Searching for Adherence: Can We Fulfill the Promise of Evidence-Based Medicines?

Journal of the American College of Cardiology

Volumn 68, Issue 8, 2016, Pages 802-804

  Armstrong, Paul W ^a   McAlister, Finlay A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

adherence; medicines; outcomes

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; MEDICATION COMPLIANCE;

EVIDENCE-BASED MEDICINE; MEDICATION ADHERENCE;

EID: 84990236982     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.06.006     Document Type: Editorial

References (22)

1. 1 Steve Forbes: A chat with a candidate [transcript]. AllPolitics Chat. CNN, March 16, 1999.
2. 2 Ford, E.S., Ajani, U.A., Croft, J.B., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 356 (2007), 2388–2398.
3. 3 Majumdar, S.R., McAlister, F.A., Furberg, C.D., From publication to practice in chronic cardiovascular disease: a long and winding road. J Am Coll Cardiol 43 (2004), 1738–1742.
4. 4 GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) registry: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 141 (2001), 190–199.
5. 5 Ohman, E.M., Bhatt, D.L., Steg, P.G., et al., REACH Registry Investigators. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 151 (2006), 786.e1–786.e10.
6. 6 Hoekstra, J.W., Pollack, C.V. Jr., Roe, M.T., et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. Acad Emerg Med 9 (2002), 1146–1155.
7. 7 LaBresh, K.A., Gliklich, R., Liljestrand, J., et al. Using “Get With the Guidelines” to improve cardiovascular secondary prevention. Jt Comm J Qual Saf 29 (2003), 539–550.
8. 8 Bansilal, S., Castellano, J.M., Garrido, E., et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J Am Coll Cardiol 68 (2016), 789–801.
9. 9 Chowdhury, R., Khan, H., Heydon, E., et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 34 (2013), 2940–2948.
10. 10 Sokol, M.C., McGuigan, K.A., Verbrugge, R.R., et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43 (2005), 521–530.
11. 11 Jackevicius, C.A., Li, P., Tu, J.V., Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117 (2008), 1028–1036.
12. 12 Andrade, S.E., Walker, A.M., Gottlieb, L.K., et al. Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings?. N Engl J Med 332 (1995), 1125–1131.
13. 13 Sarrazin, M.S., Rosenthal, G.E., Finding pure and simple truths with administrative data. JAMA 307 (2012), 1433–1435.
14. 14 Simpson, S.H., Eurich, D.T., Majumdar, S.R., et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ, 333, 2006, 15.
15. 15 Packer, M., Poole-Wilson, P.A., Armstrong, P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100 (1999), 2312–2318.
16. 16 Halpern, M.T., Khan, Z.M., Schmier, J.K., et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 47 (2006), 1039–1048.
17. 17 Peterson, E.D., Roe, M.T., Mulgund, J., et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 295 (2006), 1912–1920.
18. 18 Nieuwlaat, R., Wilczynski, N., Navarro, T., et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev, 2014 (11):CD000011.
19. 19 Kardas, P., Lewek, P., Matyjaszczyk, M., Determinants of patient adherence: a review of systematic reviews. Front Pharmacol, 4, 2013, 91.
20. 20 Brookhart, M.A., Patrick, A.R., Schneeweiss, S., et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 167 (2007), 847–852.
21. 21 McAlister, F.A., Youngson, E., Bakal, J.A., et al. Impact of physician continuity on death or urgent readmission after discharge among patients with heart failure. CMAJ 185 (2013), E681–E689.
22. 22 Hines, R., Stone, N.J., Patients and physicians beliefs and practices regarding adherence to cardiovascular medication. JAMA Cardiol 1 (2016), 470–473.